Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Inds is currently trading at Rs. 582.55, up by 11.75 points or 2.06% from its previous closing of Rs. 570.80 on the BSE.

The scrip opened at Rs. 578.00 and has touched a high and low of Rs. 584.00 and Rs. 578.00 respectively. So far 13,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 593.95 on 14-Mar-2012 and a 52 week low of Rs. 423.10 on 23-May-2011.

Last one week high and low of the scrip stood at Rs. 585.00 and Rs. 559.00 respectively. The current market cap of the company is Rs. 60,325 crore.

The promoters holding in the company stood at 63.72% while Institutions and Non-Institutions held 25.56% and 10.73% respectively.

Sun Pharmaceutical Industries’ subsidiary has been granted USFDA’s approval for its Abbreviated New Drug Application (ANDA) for generic version of Seroquel, Quetiapine Fumarate Tablets, in multiple strengths.

These generic Quetiapine Fumarate tablets, 25 mg (base), 50 mg (base), 100 mg (base), 200 mg (base), 300 mg (base) and 400 mg (base) are therapeutic equivalents of AstraZeneca LP’s Seroquel tablets of similar strengths.

Quetiapine Fumarate tablets have annual sale of approximately $4.5 billion in the US. Quetiapine Fumarate tablets are indicated for the treatment of schizophrenia and acute treatment of manic episodes associated with bipolar I disorder, both as monotherapy and as an adjunct to lithium or divalproex. It is also indicated for acute treatment of depressive episodes associated with bipolar disorder as well as maintenance treatment of bipolar I disorder as an adjunct to lithium or divalproex.

Sun Pharmaceutical Industries is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.